Design: Statewide claims-based retrospective cohort
Population: 11,519 men naive to anticholinergics or beta-3 agonists having BPH surgery, Michigan
Primary outcome: New anticholinergic or beta-3 agonist use at 3 to 12 months
Effect: 12-month incidence 5.7% to 11%; vaporisation vs TURP HR 1.49 (95% CI 1.25 to 1.79)

A Michigan statewide claims study identified 11,519 men who had surgery for benign prostatic hyperplasia between 2017 and 2022 and had never used an anticholinergic or beta-3 agonist. It measured new prescriptions for these drugs between three and twelve months after surgery.

Cumulative incidence at 12 months ranged from 5.7% after transurethral microwave thermotherapy to 11% after photoselective vaporisation. Compared with transurethral resection, photoselective vaporisation carried a higher hazard (HR 1.49, 95% CI 1.25 to 1.79). Previous BPH medication and anticoagulant use were associated with higher risk; preoperative catheter dependence with lower risk.

Storage symptoms after outlet surgery disappoint patients who expected relief. These figures give a realistic number to quote when counselling.

Claims data show prescriptions, not symptoms, and procedure choice reflects prostate size and patient factors that could explain some differences.

Tell men that about 1 in 10 may need a bladder medicine within a year of BPH surgery.
Ask about urgency and frequency before surgery; they may persist afterwards.
Men on anticoagulants or previous BPH drugs were more likely to need treatment.
Review storage symptoms at follow-up rather than assuming outlet surgery fixed them.

Why it matters

Clearing the outlet does not always settle the bladder, and patients should hear that before surgery.

The statistics, in plain English

An HR of 1.49 means about half as much again the rate of starting these drugs after vaporisation compared with resection. Prescriptions are a proxy for symptoms, so the true burden may differ.